种族与社会经济地位对治疗性临床试验筛选和入组的影响
该研究基于UCSF肿瘤委员会登记库的988例成人胶质瘤患者,分析治疗性临床试验筛选与入组率。初诊时筛选率43.6%、入组率17.5%,复发时分别为49.8%和26.3%。单因素分析仅州内居住地、距医院距离和WHO分级与入组相关,少数族裔身份、保险类型、收入中位数和贫困比例与入组无关。
要点
- 初诊时43.6%患者被筛选、17.5%入组治疗性临床试验。
- 复发时49.8%患者被筛选、26.3%入组临床试验。
- 少数族裔和社会经济地位未影响成人胶质瘤临床试验入组。
核心结论
- 少数族裔身份和社会经济地位未影响成人胶质瘤治疗性临床试验的入组。
- 接近三级癌症中心可能是少数族裔患者入组的重要考虑因素。
- 应仔细考虑患者筛选以避免基于少数族裔和社会经济地位的偏倚。
研究设计与样本
- 从UCSF肿瘤委员会登记库识别988例成人患者,分析治疗性临床试验筛选和入组率。
主要发现
- 初诊时43.6%的胶质瘤患者被筛选、17.5%入组治疗性临床试验。
- 复发时49.8%的患者被筛选、26.3%入组临床试验。
- 单因素分析中,仅州内居住地、距医院距离和WHO分级与初诊和复发时入组相关。
- 少数族裔身份、保险类型、家庭收入中位数和贫困比例与临床试验入组无关。
临床怎么用
- 在成人胶质瘤患者中,不应基于少数族裔或社会经济地位预判临床试验入组可能性。
- 对少数族裔患者,可关注其距三级癌症中心的距离以促进临床试验参与。
- 临床试验筛选过程应规范以避免基于少数族裔和社会经济地位的偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Under-enrollment in clinical trials significantly limits valid analyses of clinical interventions and generalizability of findings. Often it results in premature study termination, with estimates of 22% to 50% of clinical trials terminated due to poor accrual. Currently, there are limited reports addressing the influence of race/ethnicity and socioeconomic status on clinical trial enrollment in adult glioma patients. The goal of this study was to test the hypothesis that race and socioeconomic status negatively impact therapeutic clinical trial enrollment. METHODS: 988 adult patients were identified from the UCSF Tumor Board Registry and analyzed to determine the rate of therapeutic clinical trial screening and study enrollment. RESULTS: At initial diagnosis, 43.6% and 17.5% of glioma patients were screened and enrolled in a therapeutic clinical trial, respectively. At recurrence, 49.8% and 26.3% of patients were screened and enrolled in a clinical trial, respectively. Thirty-three percent of the study population belonged to a NIH-designated underrepresented minority group; Asian/Pacific-Islander comprised 19.6% of the overall cohort. On univariate analysis, only in-state location, distance to the hospital, and WHO grade were associated with enrollment at initial diagnosis and recurrence. Minority status, insurance type, median household income, and percent below poverty were not associated with clinical trial enrollment. CONCLUSION: Minority and socioeconomic status did not impact adult glioma clinical trial enrollment. Proximity to the tertiary care cancer center may be an important consideration for minority patients. Patient screening should be carefully considered in order to avoid bias based on minority and socioeconomic status.
引用
- Morshed RA, Reihl SJ, Molinaro AM, et al. The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollment. J Neurooncol. 2020. PMID: 32350780. doi:10.1007/s11060-020-03503-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。